ESMO 2023

My highlights of ESMO23 in metastatic breast cancer

5 year follow-up

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with…

DATO-DX - where is it going?

Lu-PSMA leads forward

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining…

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

Amivantamab as a new SoC for EGFR Exon 20…

Perioperativ immunotherapy for all resectable stage…

Tarlatamab in SCLC

ALINA - immediate change of practice!

My highlights from ESMO 2023

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

What is your definition of triple-negative breast…

New and better biomarkers are needed!

What was the most exciting news at ESMO23?

MonarchE - trial update

My highlights of ESMO23 in early breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

Our guidelines are correct

5 year follow-up

Highlights in eBC

Metabolomics reveal differential expression of OMEGA 3…

Consolidation of data in early HR+ and triple-negative…

Prognostic score in early HR+/HER2-BC: translational…

Detailed view of nodal-negative patients

ER-low corresponds diagnostically to ER-0 breast cancer

Negative EFS results from NeoTrip

Preoperative checkpointinihition in ER+ disease

Use of immunotherapy in the perioperative setting of…

HR+ study with > 20 % PCR

Neoadjuvant IO - is their new strategy in HR+ breast…

Ribociclib effective in all subtypes

Analysis of tumour microenvironment and…

Clinically relevant effect of pembro also in PCR

Immunoncology in eBC - triple negative and more?

New data on neoadjuvant immunotherapy

MonarchE - mise à jour de l'essai

Nouvelles données sur l'immunothérapie néoadjuvante

Studio NeoTrip: negativi i risultati

Punti salienti in eBC

Improvement of therapy outcome by app-based patient…

ADCs in HER2+, HER2low and TNBC - what is the future of…

How to organize a molecular tumorboards in breast…

New ADC for metastatic breast cancer?

New targets, new linker, new ADCs - much more to learn…

Even more new generation ADCs in breast cancer?

Fulvestran better than anastrozole, but no survival…

Our guidelines are correct

Duvalumab + Dato-DXd effective

OP seems to be dispensable for super responders

OP-1250 (Palezestrant) confirms the role of SIRDs after…

HS20089 - a novel ADC is coming for TNBC

Remarkable efficacies in patients with HER2+ mBC with…

DATO-DX - where is it going?

Dato-DXd - new player in advanced luminal disease

Benefit for SG even after intensive pretreatment

ADC + Immunotherapy - the BEGONIA study paradigm

TROP2 expression as a potential mechanism of resistance…

T-DXd in HER2+ patients with brain metastases

Improved oncological therapy with the smartphone

New ADC in HR+ disease

TULIP: Trastuzumab duocarmazine without OS benefit

Highlights in mBC

Can surgery be spared following primary systemic…

HER2DX in the PHERgain trial

Abemaciclib remains consistent in 5-year follow-up

Robust data from the monarchE

T-DXd also effective for brain metastases

T-DXd - new standard of care for brain mets?

Still on track for success in HER2-low MBC

My highlights of ESMO23 in metastatic breast cancer

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Lo studio BEGONIA nelle paziento con tumore triplo…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

T-DXd - nowy standard postępowania w przerzutach do…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

HER2DX en el estudio PHERgain

The optimal timing of RT after radical prostatectomy…

What is the future of immune therapy in prostate…

Targeted therapy will move forward - but more robust…

Precision medicine at mCRCP

PSMAfore unleashes urooncologic opportunity

PSMA FORE: Trial and controversies

IO therapy in metastatic prostate cancer.

Salvage radiotherapy the new standard

TITAN: ultra-low PSA = best prognosis

When immunotherapy is probably not the best choice: The…

EMBARK - Quality of Life

Lu-PSMA leads forward

RADICALS RT: Trial and controversies

Big data and AI prediction tools

Negative data for pembrolizumab in mHSCPC & mCRPC

Embark without fear

Brave New World in mCRPC

EMBARK expands ENZA indication to PCa

Immunotherapy in metastatic PCa

Early use of enzalutamide in advanced prostate cancer

Longterm toxicity of adjuvant RT after prostatectomy

CXCR2 inhibitor in PCa

ENZA P:Trial and controversies

STAMPEDE. Bone prediction not for everyone - better…

Combination of radioligand therapy with chemotherapy…

CXCR2 hämmare och prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Cuando la inmunoterapia probablemente no es la mejor…

EMBARK och livskvalitet

Big Data och AI för prediktion vid prostatacancer

Part1: New standard of care in first line urothelial…

FGFR inhibitors and ADC combinations in urothelial…

New SoC in firstline bladder cancer

Amazing new data in bladder cancer

Chemo-IO establishes itself in the first-line treatment…

DAD, DAD-IO

Unique bladder delivery system of gemcitabine herolds…

The FGFR story in bladder cancer at ESMO23

FGFR inhibitors: What is the best scenario for this…

EV + Pembro as standard of care in first-line therapy…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Reescribiendo la historia de una enfermedad: Nuevo…

Inhibidores de FGFR: Cual es el mejor escenario para…

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of…

New mode of action in mRCC - ready for prime time?

Belzutifan - whats next kidney cancer?

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Kidney cancer highlights at ESMO23

Intermittent therapy also possible with TKIs

ALINA - remarkably positive DFS in early-stage ALK+…

ALINA - immediate change of practice!

ALINA - a new paradigm in operated NSCLC with…

Big improvements in early stage and a subset of…

Circulating DNA in AEGEAN trial

Scene is set for inductive immunotherapy

Perioperativ immunotherapy for all resectable stage…

Perioperative IO: OS-benefi from KEYNOTE-671

Neoadjuvant chemo-immunotherapy new standards in early…

Substantial improvement in local regional NSCLC

My highlights from ESMO 2023

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

I miei punti salienti di ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

ESMO2023-impact on everyday practice!

Activating EGFR-mutation - what's coming up?

Rare oncogenic alterations: landmark results on exon 20…

MARIPOSA II: Trial and controversies

LIBRETO - a positive study, but was it necessary?

Amivantamab upfront? MARIPOSA trial

Big improvements in early stage and a subset of…

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

By unanimous decision and still the champion –…

Amivantamab as a new SoC for EGFR Exon 20…

Does immunotherapy still have a place in EGFR-positive…

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

TROPION-Lung01: positive development

NRG fusions: a new drugable target?

New standard of care for metastatic EGFR exon 20…

Changing treatment landscape in EGFR-mutated NSCLC

Brain metastases – options to improve the systemic…

Substantial improvement in rare alterations

Amivantamab at progression? MARIPOSA-2 trial

Do ADCs have brain activity?

Practice changing results on exon 20 insertion mNSCLC

Adagrasib + pembrolizumab in patients with KRASG12C…

PAPILLON - bringing together therapy for the 1st line

Treatment sequences for EGFR-mutated Patients

Gros progrès dans les traitments medicaeux des stades…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Heeft immunotherapie nog een plek in de behandeling van…

Amivantamab at progression? MARIPOSA-2 trial

Les points forts de l'ESMO 2023

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Amivantamab upfront? MARIPOSA trial

Quelles séquences thérapeutiques pour les patients EGFR…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

I miei punti salienti di ESMO 2023

A new option in relapsed SCLC

Tarlatamab in SCLC

Evolution of the revolution - the RUBY trial

New data on sarkomas

Update on gynaecological cancers

PCO Therapeutics

Precision oncology in CUP

New data on H&N Cancer